Offer - Urjas Oil for just ₹ 1 X
Olkem Trio 12.5 Tablet is a prescription medicine that is available as a Tablet. Olkem Trio 12.5 Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Olkem Trio 12.5 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Olkem Trio 12.5 Tablet also has some side effects, the most common being Upper respiratory tract infection, Loss of appetite, Gastric Irritation. While these are the most often observed Olkem Trio 12.5 Tablet side effects, there are can be others also. These have been listed below. Normally, these side effects of Olkem Trio 12.5 Tablet are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Olkem Trio 12.5 Tablet is Mild for pregnant women and Mild for women who are breastfeeding. It is important to know if Olkem Trio 12.5 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Olkem Trio 12.5 Tablet related warnings section.
Olkem Trio 12.5 Tablet is contraindicated in people with pre-existing medical conditions like Bradycardia (Slow Heart Rate), Low Blood Pressure (Hypotension), Low Blood Pressure (Hypotension) as it can result in adverse effects. Some other conditions that can be affected by Olkem Trio 12.5 Tablet are listed in the contraindications section below.
Drug reaction of Olkem Trio 12.5 Tablet with other medicines has been reported. See below for a complete list.
You should also be aware that Olkem Trio 12.5 Tablet is not safe while driving, and is not addiction.
Olkem Trio 12.5 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Olkem Trio 12.5 Tablet safe for pregnant women?
Pregnant women may get mild side effects from Olkem Trio.
Is the use of Olkem Trio 12.5 Tablet safe during breastfeeding?
Olkem Trio has been seen to have minimal side effects on breastfeeding women.
What is the effect of Olkem Trio 12.5 Tablet on the Kidneys?
Olkem Trio rarely harms the kidneys.
What is the effect of Olkem Trio 12.5 Tablet on the Liver?
Olkem Trio may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Olkem Trio 12.5 Tablet on the Heart?
Olkem Trio has very mild side effects on the heart.
Olkem Trio 12.5 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Olkem Trio 12.5 Tablet unless your doctor advises you to do so -
Is this Olkem Trio 12.5 Tablet habit forming or addictive?
No, there is no any evidence that Olkem Trio 12.5 Tablet is addictive.
Interaction between Food and Olkem Trio 12.5 Tablet
Taking Olkem Trio 12.5 Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Olkem Trio 12.5 Tablet
Consult your doctor before consuming alcohol while taking Olkem Trio 12.5 Tablet as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Thalitone ® (chlorthalidone)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 583-584
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448